Drug Discount Programs Create More Cloud In Quest For Transparency
Executive Summary
Behind a popular drug discount program are pharmacy benefits managers and even drug companies themselves, raising questions about whether such businesses may yet be another player in an opaque and complicated supply chain that is facilitating higher US drug prices, even as the most prominent company in the space, GoodRx, routinely criticizes soaring list prices.
You may also be interested in...
Diabetes, Blood-Thinners Dominate Copay Support, But Assistance May Not Be Well Targeted To Need
New comprehensive study of drug coupons offered by manufacturers, pharmacies, pharmacy benefit managers and state programs, and who uses the discounts, takes a more holistic look at patient assistance programs than previous work. Researchers raise concerns that the offsets don’t seem well targeted at people with high financial or clinical need.
Lower Reimbursement For Accelerated Approval Drugs May Get Push From ICER
ICER President Steve Pearson expresses interest in setting drug costs for accelerated approval drugs low with price increases based on confirmatory evidence ahead of upcoming white paper from the group.
Woodcock: COVID Is Not The Time For Structural Changes At US FDA
Acting FDA Commissioner Janet Woodcock says FDA is interested in establishing new ‘Centers of Excellence’ but the current environment is not the right time to make changes at the agency. Woodcock also talked about where FDA will spend its new pandemic money and its reexamination of accelerated approval drugs in a wide-sweeping conversation with the Alliance for a Stronger FDA.